Arcturus Therapeutics Holdings (ARCT) Stock Overview
Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ARCT Community Fair Values
Create NarrativeSee what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Arcturus Therapeutics Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.22 |
| 52 Week High | US$24.17 |
| 52 Week Low | US$8.04 |
| Beta | 2.39 |
| 1 Month Change | -49.39% |
| 3 Month Change | -21.98% |
| 1 Year Change | -40.79% |
| 3 Year Change | -35.37% |
| 5 Year Change | -79.25% |
| Change since IPO | 12.09% |
Recent News & Updates
Arcturus Therapeutics: CF Setback Reinforces The Risks Of Its mRNA Therapeutics
Oct 23Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 32% Jump Looks Justified
Aug 29
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?
Jul 31Recent updates
Arcturus Therapeutics: CF Setback Reinforces The Risks Of Its mRNA Therapeutics
Oct 23Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 32% Jump Looks Justified
Aug 29Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?
Jul 31Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41%
May 04
KOSTAIVE Approval And Upcoming Vaccine Trials Will Open New Markets
European approval of the mRNA COVID-19 vaccine could significantly boost sales through broader market access in 31 countries.Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet
Mar 20Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results
Mar 09Arcturus: Downgrading As mRNA Promise Meets Market Reality
Jan 28Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Nov 14Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified
Oct 04Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Shareholder Returns
| ARCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -45.7% | -0.3% | 2.0% |
| 1Y | -40.8% | 2.3% | 17.9% |
Return vs Industry: ARCT underperformed the US Biotechs industry which returned 2.3% over the past year.
Return vs Market: ARCT underperformed the US Market which returned 17.9% over the past year.
Price Volatility
| ARCT volatility | |
|---|---|
| ARCT Average Weekly Movement | 21.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARCT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ARCT's weekly volatility has increased from 14% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 175 | Joe Payne | arcturusrx.com |
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis.
Arcturus Therapeutics Holdings Inc. Fundamentals Summary
| ARCT fundamental statistics | |
|---|---|
| Market cap | US$304.67m |
| Earnings (TTM) | -US$60.16m |
| Revenue (TTM) | US$122.12m |
Is ARCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARCT income statement (TTM) | |
|---|---|
| Revenue | US$122.12m |
| Cost of Revenue | US$193.05m |
| Gross Profit | -US$70.93m |
| Other Expenses | -US$10.76m |
| Earnings | -US$60.16m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.22 |
| Gross Margin | -58.08% |
| Net Profit Margin | -49.27% |
| Debt/Equity Ratio | 0% |
How did ARCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/26 02:46 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arcturus Therapeutics Holdings Inc. is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |